Director, Early Clinical and Translational Development @ (November 2018 - May 2020)
Director, Clinical and Translational Medicine, Lead of Hematology-Oncology Franchises @ (May 2017 - November 2018)
Director, Lead of Translational Medicine-Oncology @ (September 2015 - May 2017)
Director, Early Clinical and Translational Medicine Expert, Oncology @ (April 2014 - August 2015)
Senior Clinical Biomarker Lead of Biology-Biomarkers @ (June 2012 - February 2014)
Principal Scientist, Head of pharmacodynamic biomarkers and mechanism of action group @ ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (February 2010 - May 2012)
Senior Scientist III @ ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company (February 2008 - February 2010)
Assistant Professor @ Weill Cornel Medical College (January 2004 - February 2008)
Principal Investigator @ Memorial Sloan Kettering Cancer Center, (January 2002 - January 2007)
Post Doctoral Research Fellow @ Institute Pasteur, Paris (January 1999 - January 2002)
Visiting Research Fellow @ GENETHON-Centre (January 2000 - January 2001)
Selda Samakoglu Education
Erasmus University School of Medicine in Rotterdam, Holland / Akdeniz University in Antalya, Turkey
Ph.D (Molecular Biology and Medical Biology)
1993-1998
Hacettepe University in Ankara, Turkey / Mt Sinai School of Medicine
MD (Medicine / Oncology)
Selda Samakoglu Skills
Oncology
Cell
ELISA
Molecular Biology
In Vivo
Biomarkers
Cancer
Lifesciences
Assay Development
Pharmacology
PCR
Clinical Development
Drug Development
Immunohistochemistry
Genomics
Animal Models
Genetics
GLP
Clinical Trials
Translational Research
Antibodies
Biotechnology
Biomarker Discovery
Cell Biology
Clinical Research
FACS
Good Laboratory Practice (GLP)
Immunology
Life Sciences
Monoclonal Antibodies
RNAi
CMO management
Project Management
Regulatory Affairs
Research and Development (R&D)
Working with Investors
Leadership
Public Speaking
Biology
Strategy
Medicine
Program Management
Management
Science
Services
Hospitals
Research
Good Laboratory Practice Glp
Cell Culture
Good Laboratory Practice
Selda Samakoglu Summary
Selda Samakoglu, based in Bedford, MA, US, is currently a Chief Medical Officer at Aveta Biomics Inc. Selda Samakoglu brings experience from previous roles at Iovance Biotherapeutics, Inc., Replimune, CSL Behring, Early Clinical Development Program, Inherited Forms of Anemias, Thr and Bristol-Myers Squibb. Selda Samakoglu holds a 1993 - 1998 Ph.D in Molecular Biology and Medical Biology @ Erasmus University School of Medicine in Rotterdam, Holland / Akdeniz University in Antalya, Turkey. With a robust skill set that includes Oncology, Cell, ELISA, Molecular Biology, In Vivo and more. Selda Samakoglu has 4 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Selda Samakoglu?
Find contact details for 700 million professionals.